Emergent BioSolutions EBS 深 沪
已收盘 08-22 16:00:00 美东时间
9.23
-0.090
-0.97%
华盛通- 最 高9.66
- 今 开9.45
- 成交量 123.78万股
- 最 低 9.225
- 昨 收 9.32
- 总市值 5.01亿
- 52周最高 12.73
- 市盈率 静 --
- 换手率 2.28%
- 52周最低 4.02
- 委 比 98.86%
- 总股本 5427.78万
- 历史最高 137.61
- 量 比 1.19
- 振 幅 4.67%
- 历史最低 1.42
- 每 手 1
- 风险率 1.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
Emergent BioSolutions partners with advocacy groups for National Fentanyl Prevention and Awareness Day, raising awareness about fentanyl risks and promoting life-saving naloxone. The campaign emphasizes the dangers of synthetic opioids like fentanyl, responsible for 70% of overdose deaths. Billboards in Times Square highlight the importance of reducing stigma around opioid poisonings and increasing access to naloxone. Emergent's "Ready to Rescue"...
08-21 12:45
美股牛股 | Firefly航天上市首日飙涨34%！季报超预期，Sunrun、AVAH绩后股价集体大涨
Firefly航天上市首日大涨34%！总市值达85亿美元；Q2季报超预期，AVAH绩后飙涨49%，太阳能概念Sunrun大涨32%>>
08-08 15:45
Emergent BioSolutions shares are trading higher after the company reported better-than-expected Q2 financial results.
Emergent BioSolutions shares are trading higher after the company reported bett...
08-07 05:55
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
A Preview Of Emergent BioSolutions's Earnings
Emergent BioSolutions (NYSE:EBS) will release its quarterly earnings report on ...
08-06 01:04
Emergent BioSolutions Publishes Comprehensive Review On Brincidofovir For Mpox In 'Expert Review of Anti-infective Therapy' Journal
Emergent BioSolutions Inc. (NYSE:EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1
07-28 20:53
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Emergent BioSolutions Inc. has published a review article on brincidofovir's potential in treating mpox, highlighting its antiviral properties, clinical trial progress in Africa, and combination therapy possibilities.Mpox, declared a global health emergency, remains a significant threat, driving the need for effective treatments.
07-28 12:50
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
Emergent BioSolutions praises the U.S. House of Representatives for installing OTC naloxone at all AED locations, a move led by Representative Buddy Carter to address the opioid overdose crisis. Emergent highlights its role in expanding access to life-saving treatments like NARCAN® Nasal Spray 4 mg and KLOXXADO® Nasal Spray 8 mg. The company emphasizes the importance of naloxone availability, as opioid overdoses can occur anytime, anywhere. Since...
07-28 12:50
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
Emergent BioSolutions将于2025年8月6日下午5点东部时间召开电话会议，讨论2025年第二季度的财务结果。参与者可通过网络直播或访问投资者页面，或提前注册电话会议参与。会议结束后，可在投资者页面访问重播。Emergent BioSolutions是一家专注于开发针对多种健康威胁的防护和救生解决方案的公司，包括小pox、mpox、botulism、Ebola、antrax和阿片类药物过量危机等。投资者和媒体可通过提供的联系方式获取更多信息。
07-15 11:30
Emergent BioSolutions signs contract modification award for CNJ-016
Emergent BioSolutions (NYSE:EBS) announced a modification to its contract to provide its smallpox vaccine, CNJ-016, to the Administration for Strategic Preparedness and Response, part of the U.S. Depa...
07-09 05:25
